The Next Wave In Cancer Treatment - Kinase Inhibitors

Jan 08, 2013, 07:48 ET from Reportlinker

NEW YORK, Jan. 8, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Next Wave In Cancer Treatment - Kinase Inhibitors

http://www.reportlinker.com/p01080628/The-Next-Wave-In-Cancer-Treatment---Kinase-Inhibitors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This Kalorama Information report – The Next Wave in Cancer Treatment – Kinase Inhibitors - is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including:

- Breast

- Colorectal

- Head/Neck

- Kidney

- Leukemia

- Liver

- Lung

- Melanoma

- Ovarian

- Pancreatic

- Prostate

- Stomach

The report covers both currently marketed and late stage development kinase inhibitors for cancer treatment. Revenues for this market segment were generated using dollar and unit sales for each product.

The report includes statistical information for relevant cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. The market segments provide an overview, description of kinase inhibitors currently on the market, leading product sales, market estimates and forecasts, and competitive analysis of leading providers. The report also includes a list of products in development and current issues and trends affecting the cancer industry as a whole.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers' level. The base year for data was 2012. Historical data was provided for the years 2007 through 2011, with forecast data provided for 2013 through 2017. Compound annual growth rates (CAGRs) are provided for the 2007-2012, 2012-2017 and 2007-2017 periods for each industry segment covered. Competitive analysis is provided for the year 2012. The forecasted market analysis for 2013-2017 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, and demographic trends.

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction Scope and Methodology Tyrosine Kinase Inhibitors (TKIs) Market Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors

CHAPTER TWO: INTRODUCTION

What is Cancer?

Biochemistry of Cancer Cells

Carcinogen Metabolism

Causes of Cancer Growth

Environmental Factors, DNA, RNA

Cellular Oncogenes

Tumor Suppressor Genes

History and Growth of the Cancer Treatment Market

Industry Structure

Demographics and Statistics

Global Cancer Statistics

Lung Cancer

Breast Cancer

Colon/Rectal Cancer

Cancer Stats in the United States

Demographics

Aging Population

Life Expectancy and Cancer

Life Expectancy

Birth Rates

Description of Select Cancers

Breast Cancer

Colorectal Cancer

Head and Neck

Kidney

Leukemia

Liver

Lung Cancer

Melanoma

Ovarian Cancer

Pancreas

Prostate Cancer

Stomach Cancer

CHAPTER THREE: PRODUCTS

OverviewBosulif (bosutinib) Caprelsa (vandetanib) Gleevec (imatinib) Inlyta (axitinib) Iressa (gefitinib) Jakafi (ruxolitinib) Nexavar (sorafenib) Sprycel (dasatinib) Stivarga (regorafenib) Sutent (sunitinib) Tarceva (erlotinib) Tasigna (nilotinib) Tyverb/Tykerb (lapatinib) Votrient (pazopanib) Xalkori (crizotinib) Zelboraf (vemurafenib)

CHAPTER FOUR: MARKET SIZE AND GROWTH

Market Summary

Markets by Geographical Segments

U.S. Market

Europe Market

Japan Market

ROW Market

Competitive Analysis

CHAPTER FIVE: NEW DEVELOPMENTS

The Pipeline for Kinase InhibitorsSignificant DevelopmentsAfatinib Axitinib Bosutinib Cabozantinib Crizotinib Motesanib Ponatinib Regorafenib Tivozanib Recent NDA Activity New Approvals Patent Activity and Generic Development

CHAPTER SIX: ISSUES AND TRENDS

Introduction

Insurance and Reimbursement Issues

Personalized Medicine

Targeted Cancer Therapy

Pharmacogenomics

Alliances Acquisitions and Licensing Agreements

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Eli Lilly & Co.

Johnson & Johnson

Merck

Novartis

Pfizer

Patient-Reported Outcomes

Healthy Lifestyles Continue to Show Promise for Cancer Prevention

Obesity in the U.S.

U.S. Obesity Rates Differ Among Ethnic Groups

Alcohol's Affect on Cancer Incidence

Marketing and Distribution Trends

Geographical Trends

United States

Europe

Japan

Elderly Clinical Trial Involvement

CHAPTER SEVEN:COMPANY PROFILES

Introduction AstraZeneca plc Bayer Bristol-Myers Squibb Company GlaxoSmithKline Novartis Pfizer, Inc. Roche

APPENDIX:MAJOR COMPETITORS' ADDRESSES

CHAPTER ONE: EXECUTIVE SUMMARY

Figure 1-1: Sales of Kinase Inhibitor Products, 2012 Figure 1-2: World Cancer Kinase Inhibitor Market, 2007-2017 Table 1-1: World Cancer Kinase Inhibitor Market, 2007-2017 Figure 1-1: World Cancer Kinase Inhibitor Market, 2007-2017 w/ Growth Trend

CHAPTER TWO: INTRODUCTION

Table 2-1: Viruses Associated with Cancer in Humans

Figure 2-1: Approved Cancer Therapies in the United States by

Primary Indication

Figure 2-2: Approved Kinase Inhibitors for Cancer Treatment

in the United States by Original Indication*

Table 2-2: Total Cancer Incidence by Gender and Country, 2010 Estimates

Figure 2-3: Cancer Incidence by Gender and Country, 2010 Estimates

Table 2-3: World Cancer Incidence by Selected Types of Cancer, 2010 and

2020, all races, both genders

Figure 2-4: Estimated and Projected World Cancer Incidence by

Selected Types of Cancer, 2010 and 2020

Table 2-4: Most Common Cancer by Region and Gender

Table 2-5: United States: Total Cancer Incidence by Gender, 2012 Estimates

Figure 2-5: United States: Total Cancer Incidence by Gender, 2012 Estimates

Table 2-6: United States: Total Cancer Deaths by Gender, 2012 Estimates

Figure 2-6: United States: Total Cancer Deaths by Gender, 2012 Estimates

Table 2-7: World Population by Selected Geographical Region, 2010 - 2050

Figure 2-7: World Population by Selected Geographical Region, 2010–2050

Table 2-8: Percent Population Over 65 by Year and Region, 2010-2050

Figure 2-8: Estimated World Population by Age, 2010 and 2050

Table 2-9: Average Life Expectancy in Years by Country 1980 and 2011

Figure 2-9: Average Life Expectancy in Years by Country 1980 and 2011

Table 2-10: United States Average Years of Life Lost Per Person Dying of

Cancer, All Races, Both Sexes, 2009

Table 2-11: United States Estimated Person-Years of Life Lost Due to

Cancer, All Races, Both Sexes, 2009

Table 2-10: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010

Figure 2-12: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010

Table 2-11: Types of Leukemia

Table 2-12: Types of Primary Lung Cancer

Table 2-13: Malignant Conditions of the Skin

CHAPTER THREE: PRODUCTS

Table 3-1: Cancer Indicated Kinase Inhibitor Approvals by Year Figure 3-1: Table 3-2: Leading Products by Sales, 2010 and 2012

CHAPTER FOUR: MARKET SIZE AND GROWTH

Table 4-1: World Cancer Kinase Inhibitor Market, 2007-2017

Figure 4-1: World Cancer Kinase Inhibitor Market, 2007-2017

Table 4-2: World Cancer Kinase Inhibitor Market

Figure 4-2: World Cancer Kinase Inhibitors Market

Table 4-3: U.S. Kinase Inhibitor Products by Sales, 2012

Figure 4-3: U.S. Kinase Inhibitor Products by Sales, 2012

Table 4-4: Europe Kinase Inhibitor Products by Sales, 2012

Figure 4-4: Europe Kinase Inhibitor Products by Sales, 2012

Figure 4-5: World Cancer Kinase Inhibitor Market

Figure 4-6: World Cancer Kinase Inhibitor Market

Figure 4-7: World Cancer Kinase Inhibitor Market

Table 4-5: Top 5 Suppliers: Cancer Kinase Inhibitor Market – Shares

by Market Revenues, 2012

Figure 4-8: Top 5 Suppliers: Cancer Kinase Inhibitor Market – Shares

by Market Revenues, 2012

CHAPTER FIVE: NEW DEVELOPMENTS

Table 5-1: Developments in Kinase Inhibitors, Selected Projects Figure 5-1: Registration and Phase III Compounds in Development for Major Indications, Distribution Estimates Table 5-2: Recent NDA Activity: January 2011-October 2012 Table 5-3: Select New Approvals (NCE, Indications, Dosage, Formulations) January 2010-October 2012 Table 5-4: Patent Data for Kinase Inhibitors

CHAPTER SIX: ISSUES AND TRENDS AFFECTING THE

CANCER MARKET

Table 6-1: Obesity Rates by U.S. State, 2011

CHAPTER SEVEN: COMPANY PROFILES

Figure 7-1: Cancer Kinase Inhibitor Development for Leading Companies

To order this report:Pathology Industry: The Next Wave In Cancer Treatment - Kinase Inhibitors

CONTACT
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com